webinar register page

Webinar banner
WEBINAR: Redefining Transplantation with Non-Invasive Allograft Surveillance
This webinar will discuss the following topics:

- Surveillance after allograft transplantation is critical to the detection of active rejection and prevention of chronic allograft dysfunction.

- Levels of donor derive cell-free DNA (dd-cfDNA) have been observed significantly increased in active rejection versus stable patients, which is related to differences on allograft injury compared to a normal healthy status.

- By using single-nucleotide polymorphisms (SNPs) to discriminate between donor and recipient cfDNA molecules, AlloSeq cfDNA assay measures dd-cfDNA based as a clinical-grade, next-generation targeted sequencing (NGS) assay.

- Measurement of plasma dd-cfDNA at consecutive time points after transplant is a clinically useful tool for the assessment of allograft health and non-invasive surveillance for injury.

- Negative results are strongly supportive of no active injury (high NPV of 95%) and can give patients peace of mind. For transplant physicians, the test offers an opportunity to rule out rejection, and prioritise patients based on low risk for telemedicine approaches

Who should attend?
Transplant physicians; transplant immunologists; transplant coordinators; health care innovation officers

Creators and Moderators:
CareDX – Creator
Silvia Casas | Barcelona, Spain – Moderator

Miha Arnol | Ljubljana, Slovenia
Andrea Zajacova | Prague, Czech Republic
Jeroen Verhoeven | Rotterdam, Netherlands

This webinar is organised in partnership with and sponsored by CareDx.

Jun 21, 2021 06:00 PM in Rome

* Required information